SCHEMBL5134864

SCHEMBL5134864

CCCCn1c(CN(CCc2ccc(OC)c(OC)c2)Cc2ccc3c(c2)OCO3)cnc1-c1cccc(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 16/20 0.57
HTR2B P41595 16/20 0.57
HTR2C P28335 15/20 0.57
ADRB1 P08588 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
DRD2 P14416 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
DRD4 P21917 1/20 0.47
SLC6A2 P23975 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR1D P28221 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR7 P34969 1/20 0.47
ADRA1A P35348 1/20 0.47
HRH1 P35367 1/20 0.47
OPRM1 P35372 1/20 0.47
DRD3 P35462 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137540 0.96 HTR2A (0.53) HTR2AHTR2BHTR2CADRB1HTR1A
SCHEMBL5136215 0.92 HTR2A (0.57) HTR2AHTR2BHTR2CADRB1HTR1A
SCHEMBL5135288 0.91 HTR2A (0.51) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136312 0.91 HTR2A (0.44) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5137390 0.88 C5AR1 (0.44) HTR2AHTR2BHTR2CTP53
SCHEMBL4768999 0.88 C5AR1 (0.51) HTR2AHTR2BHTR2CSMN1; SMN2
SCHEMBL5136966 0.88 HTR2A (0.43) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5136963 0.87 C5AR1 (0.47) HTR2AHTR2BHTR2CSMN1; SMN2
SCHEMBL5136272 0.87 C5AR1 (0.43) HTR2AHTR2BHTR2CTP53SMN1; SMN2
SCHEMBL5135235 0.86 C5AR1 (0.54) HTR2AHTR2BHTR2CADRB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed